Sanara MedTech Reports Record $103.1M Revenue in 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2026
0mins
Should l Buy SMTI?
Source: seekingalpha
- Significant Revenue Growth: Sanara MedTech achieved a record $103.1 million in net revenue for 2025, marking a 19% year-over-year increase, which underscores the strength of its hybrid commercial model and is expected to further enhance market share.
- Distributor Network Expansion: The company expanded its network to over 450 independent distributor partners by year-end 2025, up from more than 350 in 2024, successfully penetrating over 1,450 healthcare facilities, thereby increasing market penetration and customer base.
- Strategic Focus Transformation: The completion of the wind-down of the Tissue Health Plus (THP) segment allows the company to concentrate on the surgical market, with core products like CellerateRx Surgical and BIASURGE, which are expected to lay a solid foundation for future growth.
- Optimistic Future Outlook: Management reaffirmed full-year 2026 net revenue guidance between $116 million and $121 million, representing a growth of 13% to 17%, and plans to invest in expanding the sales team and R&D to support sustainable growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SMTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SMTI
Wall Street analysts forecast SMTI stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 17.180
Low
36.00
Averages
36.00
High
36.00
Current: 17.180
Low
36.00
Averages
36.00
High
36.00
About SMTI
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sanara MedTech Reports Record $103.1M Revenue in 2025
- Significant Revenue Growth: Sanara MedTech achieved a record $103.1 million in net revenue for 2025, marking a 19% year-over-year increase, which underscores the strength of its hybrid commercial model and is expected to further enhance market share.
- Distributor Network Expansion: The company expanded its network to over 450 independent distributor partners by year-end 2025, up from more than 350 in 2024, successfully penetrating over 1,450 healthcare facilities, thereby increasing market penetration and customer base.
- Strategic Focus Transformation: The completion of the wind-down of the Tissue Health Plus (THP) segment allows the company to concentrate on the surgical market, with core products like CellerateRx Surgical and BIASURGE, which are expected to lay a solid foundation for future growth.
- Optimistic Future Outlook: Management reaffirmed full-year 2026 net revenue guidance between $116 million and $121 million, representing a growth of 13% to 17%, and plans to invest in expanding the sales team and R&D to support sustainable growth.
See More
Sanara MedTech Q4 Earnings Report Analysis
- Earnings Highlights: Sanara MedTech reported a Q4 GAAP EPS of -$0.19, yet achieved revenue of $27.5 million, reflecting a 4.6% year-over-year growth, demonstrating the company's resilience in challenging conditions.
- Future Outlook: The company anticipates full-year 2026 net revenue to range from $116 million to $121 million, representing a growth of approximately 13% to 17% compared to $103.1 million in 2025, indicating management's confidence in future growth.
- Revenue Expectations: Sanara MedTech expects Q4 revenue to be between $27.2 million and $27.7 million, aligning with actual revenue figures, which reflects the company's stable performance in the market.
- Market Reaction: Despite challenges, Sanara MedTech's financial performance and future guidance may attract investor interest, potentially supporting its stock price performance to some extent.
See More
SANARA MEDTECH INC - CONFIRMS FY2026 NET REVENUE PROJECTION OF $116-$121 MILLION, EXPECTING 13%-17% GROWTH
- Revenue Guidance: Sanara MedTech has provided revenue guidance for FY 2026, estimating between $116 million and $121 million.
- Growth Projection: The company anticipates a growth rate of 13% to 17% for the upcoming fiscal year.
See More
SANARA MEDTECH INC REPORTS 5% RISE IN Q4 2025 NET REVENUE TO $27.5 MILLION
- Revenue Growth: Sanara MedTech's revenue for Q4 2025 has increased by 5%, reaching $27.5 million.
- Financial Performance: The increase in revenue indicates a positive trend in the company's financial performance during this period.
See More
SANARA MEDTECH REPORTS ANNUAL REVENUE OF USD 103.1 MILLION
- Revenue Report: Sanara MedTech reported a revenue of USD 10.3 million.
- Financial Performance: The revenue reflects the company's growth and market presence in the medical technology sector.
See More
Sanara MedTech to Report Q4 and Full Year 2025 Results
- Earnings Announcement: Sanara MedTech is set to release its fourth quarter and full year 2025 financial results on March 24, 2026, before U.S. markets open, which is expected to provide critical performance data and future outlook for investors.
- Conference Call Details: The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the financial results and hold a Q&A session, likely attracting significant attention from analysts and investors, thereby enhancing market transparency.
- Replay Service Availability: A telephonic replay of the conference call will be available until April 7, 2026, ensuring that investors who cannot participate live can still access the information, thus improving information accessibility.
- Market Positioning: Sanara focuses on developing and commercializing innovative technologies in the surgical market aimed at achieving better clinical outcomes and reducing healthcare expenditures, highlighting its strategic importance in the North American surgical tissue repair market.
See More
Sanara MedTech Reports Record $103.1M Revenue in 2025
- Significant Revenue Growth: Sanara MedTech achieved a record $103.1 million in net revenue for 2025, marking a 19% year-over-year increase, which underscores the strength of its hybrid commercial model and is expected to further enhance market share.
- Distributor Network Expansion: The company expanded its network to over 450 independent distributor partners by year-end 2025, up from more than 350 in 2024, successfully penetrating over 1,450 healthcare facilities, thereby increasing market penetration and customer base.
- Strategic Focus Transformation: The completion of the wind-down of the Tissue Health Plus (THP) segment allows the company to concentrate on the surgical market, with core products like CellerateRx Surgical and BIASURGE, which are expected to lay a solid foundation for future growth.
- Optimistic Future Outlook: Management reaffirmed full-year 2026 net revenue guidance between $116 million and $121 million, representing a growth of 13% to 17%, and plans to invest in expanding the sales team and R&D to support sustainable growth.
See More
Sanara MedTech Q4 Earnings Report Analysis
- Earnings Highlights: Sanara MedTech reported a Q4 GAAP EPS of -$0.19, yet achieved revenue of $27.5 million, reflecting a 4.6% year-over-year growth, demonstrating the company's resilience in challenging conditions.
- Future Outlook: The company anticipates full-year 2026 net revenue to range from $116 million to $121 million, representing a growth of approximately 13% to 17% compared to $103.1 million in 2025, indicating management's confidence in future growth.
- Revenue Expectations: Sanara MedTech expects Q4 revenue to be between $27.2 million and $27.7 million, aligning with actual revenue figures, which reflects the company's stable performance in the market.
- Market Reaction: Despite challenges, Sanara MedTech's financial performance and future guidance may attract investor interest, potentially supporting its stock price performance to some extent.
See More
SANARA MEDTECH INC - CONFIRMS FY2026 NET REVENUE PROJECTION OF $116-$121 MILLION, EXPECTING 13%-17% GROWTH
- Revenue Guidance: Sanara MedTech has provided revenue guidance for FY 2026, estimating between $116 million and $121 million.
- Growth Projection: The company anticipates a growth rate of 13% to 17% for the upcoming fiscal year.
See More
SANARA MEDTECH INC REPORTS 5% RISE IN Q4 2025 NET REVENUE TO $27.5 MILLION
- Revenue Growth: Sanara MedTech's revenue for Q4 2025 has increased by 5%, reaching $27.5 million.
- Financial Performance: The increase in revenue indicates a positive trend in the company's financial performance during this period.
See More
SANARA MEDTECH REPORTS ANNUAL REVENUE OF USD 103.1 MILLION
- Revenue Report: Sanara MedTech reported a revenue of USD 10.3 million.
- Financial Performance: The revenue reflects the company's growth and market presence in the medical technology sector.
See More
Sanara MedTech to Report Q4 and Full Year 2025 Results
- Earnings Announcement: Sanara MedTech is set to release its fourth quarter and full year 2025 financial results on March 24, 2026, before U.S. markets open, which is expected to provide critical performance data and future outlook for investors.
- Conference Call Details: The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the financial results and hold a Q&A session, likely attracting significant attention from analysts and investors, thereby enhancing market transparency.
- Replay Service Availability: A telephonic replay of the conference call will be available until April 7, 2026, ensuring that investors who cannot participate live can still access the information, thus improving information accessibility.
- Market Positioning: Sanara focuses on developing and commercializing innovative technologies in the surgical market aimed at achieving better clinical outcomes and reducing healthcare expenditures, highlighting its strategic importance in the North American surgical tissue repair market.
See More
